简介：摘要当前，国内的设计单位在进行CAD工艺配管设计时，存在较多不足，需进行优化。本文主要从核心软件与配套软件，两方面出发，探讨优化CAD工艺配管软件配置的方法。

简介：摘要文章简单介绍CAD技术的概念以及在矿山测量中应用的主要作用，介绍CAD技术在矿山测量中的具体应用情况，并重点研究CAD技术与其他技术进行融合在矿山测量中的发展运用状况，以供参考。

简介：摘要目的探讨血清E-钙黏蛋白(E-cad)、血管内皮生长因子(VEGF)水平与晚期胃癌患者化疗预后的关系。方法抽取2017年1月至2020年12月山西省肿瘤医院收治的96例晚期胃癌患者，所有患者均在医院接受化疗治疗。化疗后随访1年，记录患者病死、存活情况，将病死患者纳入预后不良组，将存活患者纳入预后良好组。患者入院时接受血清E-cad、VEGF水平检测，询问患者基线资料并记录研究所需资料，分析血清E-cad、VEGF水平与晚期胃癌患者化疗预后的相关性。结果1年随访结果显示，96例晚期胃癌患者中，病死25例(26.04%)纳入预后不良组，存活71例(73.96%)纳入预好组。预后不良组入院时血清E-cad水平低于预后良好组，血清VEGF水平高于预后良好组(P<0.05)；两组其他基线资料比较差异未见统计学意义(P>0.05)。经COX回归分析结果显示，入院时血清E-cad低表达、血清VEGF高表达与晚期胃癌患者化疗预后不良有关(P<0.05)。结论血清E-cad、VEGF水平与晚期胃癌患者化疗预后有一定关系。

简介：摘要目的探讨乳腺癌中细胞增殖相关抗原（Ki-67）、表皮生长因子受体（EGFR）和上皮钙黏附蛋白（E-cad）表达及其对预后的影响。方法回顾性研究2015年5月至2021年12月连云港市第一人民医院及连云港市中医院经手术切除的乳腺癌标本167例，随访并整理患者病例资料，运用SPSS 24.0软件进行统计学分析，计数资料的组间比较采用卡方检验，采用Spearman分析评价生物学预后因子与临床病理特征、预后评价体系Neo-bioscore相关性的研究；总生存期、生存分析观察采用Kaplan-Meier法进行单因素分析并绘制生存曲线；采用Cox回归模型开展多因素分析，进一步排除混杂因素所产生的影响。结果乳腺癌标本167例，其患者平均年龄为46.4岁。（1）乳腺癌患者的病理分子分型与Ki-67、EGFR表达差异均有统计学意义（χ2=30.463、P<0.001，χ2=25.652、P<0.001）；Ki-67与EGFR，EGFR与E-cad之间的表达水平，差异均有统计学意义（χ2=7.167、P=0.007，χ2=18.576、P<0.001）。（2）EGFR与Ki-67的表达水平有紧密的正相关性（r=0.207，P=0.007），与E-cad的表达水平有显著的负相关性（r=-0.325，P<0.001）；乳腺癌Neo-bioscore评分体系分值高低与Ki-67、EGFR的表达水平均呈正相关性（r=0.324、P<0.001，r=0.176、P=0.023），与E-cad的表达水平呈负相关性（r=-0.162，P=0.037）。（3）通过Kaplan-Meier单因素及COX模型多因素生存分析显示：乳腺癌患者的Ki-67表达水平和Neo-bioscore评分是影响乳腺癌预后的因素（χ2=3.950、P=0.047，χ2=13.372，P=0.004），且为影响乳腺癌患者生存的独立危险因素。结论Ki-67、EGFR及E-cad表达对增殖活性分子表达等产生了辅助判断作用，使得个性化、靶向治疗成为可能，与乳腺癌患者的预后有直接或间接相关性，动态监测肿瘤靶向治疗效果，从而更好地为临床服务。

简介：AbstractBackground:Resting heart rate (RHR) is considered as a strong predictor of total mortality and hospitalization due to heart failure in hypertension patients. Bisoprolol fumarate, a second-generation beta-adrenoreceptor blockers (β-blocker) is commonly prescribed drug to manage hypertension. The present study was to retrospectively evaluate changes in the average RHR and its association with cardiovascular outcomes in bisoprolol-treated coronary artery disease (CAD) patients from the CAD treated with bisoprolol (BISO-CAD) study who had comorbid hypertension.Methods:We performed ad-hoc analysis for hypertension sub-group of the BISO-CAD study (n = 866), which was a phase IV, multination, multi-center, single-arm, observational study carried out from October 2011 to July 2015 across China, South Korea, and Vietnam. Multivariate regression analysis was used to identify factors associated with incidence of composite cardiac clinical outcome (CCCO), the results were presented as adjusted odds ratio (OR) along with 95% confidence interval (CI) and adjusted P value.Results:A total of 681 patients (mean age: 64.77 ± 10.33 years) with hypertension from BISO-CAD study were included in the analysis. Bisoprolol improved CCCOs in CAD patients with comorbid hypertension, with RHR <65 and <70 beats/min compared with RHR ≥65 and ≥75 beats/min, respectively, in the efficacy analysis (EA) set. In addition, it lowered RHR in both intent-to-treat (ITT) and EA groups after 6, 12, and 18 months of treatment. Further, RHR 70 to 74 beats/min resulted in significantly higher risk of CCCOs EA set of patients (adjusted OR: 4.34; 95% CI: 1.19-15.89; P = 0.03). Also, events of hospitalization due to acute coronary syndrome were higher when RHR 69 to 74 beats/min compared to RHR <69 beats/min in ITT patients.Conclusion:Bisoprolol can effectively reduce RHR in Asian CAD patients with comorbid hypertension and hence, improve CCCO without affecting their blood pressure.